5-Chloro-aMT Powder

---

5-Chloro-α-methyltryptamine, commonly referred to as 5-Chloro-αMT or PAL-542, is a tryptamine derivative that is closely related to α-methyltryptamine (αMT). It is one of the few known serotonin-dopamine releasing agents (SDRAs) and acts as a potent agonist of the serotonin 5-HT2A receptor, suggesting its potential as a serotonergic psychedelic. Research has explored its use in animals as a possible treatment for cocaine dependence.

Mechanism of Action

As a serotonin-dopamine releasing agent, 5-Chloro-αMT has demonstrated significant efficacy in promoting the release of neurotransmitters. The half-maximal effective concentration (EC50) values for the in vitro release of serotonin, dopamine, and norepinephrine in rat brain synaptosomes are reported to be 16 nM, 54 nM, and 3,434 nM, respectively. This results in a norepinephrine:dopamine ratio of 64:1 and a dopamine:serotonin ratio of 3.4:1, indicating its specificity and balanced profile as an SDRA.

Psychedelic Potential

5-Chloro-αMT is recognized as a potent full agonist of the serotonin 5-HT2A receptor, with an EC50 value of 6.27 nM and a maximal efficacy of 105%. This agonistic action suggests that 5-Chloro-αMT may induce psychedelic effects. Its close analogue, 5-fluoro-αMT, has been shown to elicit a strong head-twitch response in rats, a behavior that correlates with psychedelic effects in humans. Additionally, αMT is well-established as a psychedelic substance in human studies.

Research Findings

Studies have indicated that 5-Chloro-αMT does not reliably produce intracranial self-administration in rats, nor does it substitute for cocaine in drug discrimination tests involving rats or monkeys. Research involving rhesus monkeys has shown that norepinephrine release has minimal impact on the misuse potential of monoamine releasing agents (MRAs). Furthermore, the absence of norepinephrine release activity does not diminish the efficacy of SDRAs like 5-Chloro-αMT in reducing cocaine self-administration compared to serotonin-norepinephrine-dopamine releasing agents (SNDRAs) such as naphthylisopropylamine (PAL-287).

Advantages in Treatment

5-Chloro-αMT is expected to produce fewer side effects, including sympathomimetic and cardiovascular effects, insomnia, hyperthermia, and anxiety, compared to SNDRAs. This characteristic may make it a better-tolerated option for treating cocaine dependence and other related conditions.

Monoamine Oxidase Inhibition

Additionally, 5-Chloro-αMT is recognized as a potent monoamine oxidase inhibitor (MAOI), specifically targeting monoamine oxidase A (MAO-A). Its half-maximal inhibitory concentration (IC50) values for inhibiting MAO-A and monoamine oxidase B (MAO-B) are 250 nM and 82,000 nM, respectively. The potency of 5-Chloro-αMT in inhibiting MAO-A is comparable to that of para-methoxyamphetamine (PMA). Other related compounds, such as 5-fluoro-α-methyltryptamine (5-fluoro-αMT; PAL-544), also exhibit potent MAOI properties similar to those of 5-Chloro-αMT.

5-Chloro-aMT Powder is for research use only and not intended for human consumption!

---

5-Chloro-aMT Powder stock last updated at: April 2025